EPCAM and neoplasm: Due to the limitations of the epithelial marker EpCAM, the application of positive selection strategies that target mesenchymal (e.g., vimentin or N-cadherin), stem cell (e.g., CD133), or tumor-specific markers can be beneficial [40].